January 17, 2025 04:12 PM ESTUpdated 04:35 PM

Sage sues Biogen days after $469M buyout offer

Max Bayer

Pharma Reporter

Sage Therapeutics has sued Biogen in Delaware court, one week after receiving a $469 million buyout offer from the larger neuroscience pharma company.

The full …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Sage sues Biogen days after $469M buyout offer

Max Bayer

Pharma Reporter

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

What Trump's CMS can and can't change with the second round of drug price negotiations

Ozempic makes list for next round of Medicare drug price negotiations

FDA approves AstraZeneca and Daiichi Sankyo’s ADC for breast cancer despite lack of survival benefit

Kathy High leads GV, ARCH-backed eye disease biotech; Arvinas commercial exec steps down

Novo claims high-dose Phase 3 Wegovy win but sales impact might be muted

HHS blasts Boehringer's drug price case, reveals new details on Jardiance talks

Sage sues Bio­gen days af­ter $469M buy­out of­fer

Pharma Reporter

Sign up to read this article for free.

more like this

Bachem

Bubendorf, BL, Switzerland

Sage sues Biogen days after $469M buyout offer